is a R&D driven and innovation focused novel biopharmaceutical company. The company focuses on high-end generics as well as innovative drugs. For the high-end generics, ForeFront's portfolio includes difficult-to-synthesis molecules which may also involve semisynthetic, innovative drug delivery systems such as CR & SR formulation, fixed dose combination technologies, etc.. The company targets to file P IV and 505b2 in US and EU, and aims to file Category 1, 3, and 4 drugs in China independently and/or in collaboration with strategic partners. The company is active in Oncology, Anti-Inflammation, Antiviral, CVS, CNS disease areas for both generic and....